Mesoblast appoints Board member Joe Swedish as Non-Executive Chairman

– AUSTRALIA, Melbourne – Mesoblast Limited (Nasdaq:MESO |ASX:MSB) today announced it has appointed Joseph R. Swedish as non-executive Chairman. Mr Swedish will succeed outgoing Chairman Brian Jamieson, who is retiring from the Board on March 31, 2019.

Mesoblast Chief Executive Dr Silviu Itescu said: “As Mesoblast transitions to a commercial stage company, we welcome the deep healthcare expertise of Joe Swedish in the role of Chairman. In particular his track record in healthcare resource allocation and reimbursement metrics will be a tremendous asset as we plan our first product launch in the United States. I am very appreciative of Brian Jamieson’s valuable contributions, insights and commitment during Mesoblast’s growth and development phases.”

About Joe Swedish

Mr Swedish is a highly experienced healthcare executive and leader, most recently serving as Chairman, President and CEO of Anthem Inc., a Fortune 29 company and the leading health benefits provider in the U.S. For 12 consecutive years, Modern Healthcare named Mr Swedish as one of the 100 Most Influential People in Healthcare, ranking in the top 20 of the health sector’s most senior-level executives, high-level government administrators, elected officials, academics, and thought-leaders for five consecutive years. He has been a Mesoblast board member since June 2018, and also serves on the boards of IBM Corporation, CDW Corporation, Proteus Digital Health, and Centrexion Therapeutics.

Commenting on his appointment, Mr Swedish said: “I am very pleased to be appointed Chairman of this world-leading cellular medicines company, whose business strategy is aligned with my objectives to deliver innovative solutions to critical healthcare challenges.”

About Mesoblast

Mesoblast Limited is a world leader in developing allogeneic cellular medicines. The Company has leveraged its proprietary technology platform to establish a broad portfolio of late-stage allogeneic product candidates with three product candidates in Phase 3 trials – acute graft versus host disease, chronic heart failure and chronic low back pain due to degenerative disc disease. Through a proprietary process, Mesoblast selects rare mesenchymal lineage precursor and stem cells from the bone marrow of healthy adults and creates master cell banks, which can be industrially expanded to produce thousands of doses from each donor that meet stringent release criteria, have lot to lot consistency, and can be used off-the-shelf without the need for tissue matching. Mesoblast has facilities in Melbourne, New York, Singapore and Texas and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO).

For more information :

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>